SEC Comment Letter 0000000000-24-012798 to Galmed Pharmaceuticals Ltd. (GLMD)
Galmed Pharmaceuticals Ltd.
Date: Nov. 19, 2024 · CIK: 0001595353 · Accession: 0000000000-24-012798
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283241
Letter
November 19, 2024 Allen Baharaff Chief Executive Officer Galmed Pharmaceuticals Ltd. 16 Abba Hillel Silver Rd. Ramat Gan 5250608 Israel Re:Galmed Pharmaceuticals Ltd. Registration Statement on Form F-3 Filed November 14, 2024 File No. 333-283241 Dear Allen Baharaff: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gary Emmanuel
Show Raw Text
November 19, 2024
Allen Baharaff
Chief Executive Officer
Galmed Pharmaceuticals Ltd.
16 Abba Hillel Silver Rd.
Ramat Gan 5250608 Israel
Re:Galmed Pharmaceuticals Ltd.
Registration Statement on Form F-3
Filed November 14, 2024
File No. 333-283241
Dear Allen Baharaff:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary Emmanuel